PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
29246127-0	2017	High mobility group box 1 promotes sorafenib resistance in HepG2 cells and in vivo.	Sorafenib	35-44	high mobility group box 1	Homo sapiens	0-25	
30686534-4	2019	Both type I and II ferroptosis activators, including erastin, sorafenib, RSL3, and FIN56, induce HMGB1 release in cancer and noncancer cells.	Sorafenib	62-71	high mobility group box 1	Homo sapiens	97-102	
30123419-3	2018	In this study we established a representative panel of patient derived xenograft (PDX) mouse models from patients with renal cell carcinomas and determined serum levels of high mobility group B1 (HMGB1) protein under treatment with sunitinib, pazopanib, sorafenib, axitinib, temsirolimus and bevacizumab.	Sorafenib	254-263	high mobility group box 1	Homo sapiens	196-201	
28555325-0	2018	Erratum to: Serum HMGB1 concentrations at 4 weeks is a useful predictor of extreme poor prognosis for advanced hepatocellular carcinoma treated with sorafenib and hepatic arterial infusion chemotherapy.	Sorafenib	149-158	high mobility group box 1	Homo sapiens	18-23	
28474222-0	2018	Serum HMGB1 concentrations at 4 weeks is a useful predictor of extreme poor prognosis for advanced hepatocellular carcinoma treated with sorafenib and hepatic arterial infusion chemotherapy.	Sorafenib	137-146	high mobility group box 1	Homo sapiens	6-11	
28474222-4	2018	METHODS: Serum HMGB1 concentrations were measured in 71 and 72 patients with advanced HCC treated with sorafenib and HAIC, respectively, to assess their usefulness for prediction of the response to the treatment and prognosis.	Sorafenib	103-112	high mobility group box 1	Homo sapiens	15-20	
28474222-8	2018	CONCLUSIONS: These results suggest that serum HMGB1 at 4 weeks after the start of treatment might be a useful biomarker with added value to the conventional tumor marker and radiologic responses to predict poor overall survival in patients with advanced HCC treated with sorafenib or HAIC.	Sorafenib	271-280	high mobility group box 1	Homo sapiens	46-51	
29246127-7	2017	This study investigated the association between HMGB1 and sorafenib resistance in HCC.	Sorafenib	58-67	high mobility group box 1	Homo sapiens	48-53	
29246127-10	2017	The subcellular localization of HMGB1 in HepG2 cells following sorafenib treatment was measured by western blotting and confocal microscopy.	Sorafenib	63-72	high mobility group box 1	Homo sapiens	32-37	
29246127-12	2017	RESULTS: The HMGB1 knockdown cells exhibited a significantly higher apoptotic level and lower cell viability than the normal HMGB1 expressing cells following the sorafenib treatment.	Sorafenib	162-171	high mobility group box 1	Homo sapiens	13-18	
29246127-12	2017	RESULTS: The HMGB1 knockdown cells exhibited a significantly higher apoptotic level and lower cell viability than the normal HMGB1 expressing cells following the sorafenib treatment.	Sorafenib	162-171	high mobility group box 1	Homo sapiens	125-130	
29246127-13	2017	In addition, the cell viability observed in the HMGB1 overexpressing cells was higher than that observed in the control cells following the sorafenib intervention.	Sorafenib	140-149	high mobility group box 1	Homo sapiens	48-53	
29246127-14	2017	Sorafenib had a better tumour inhibition effect in the HMGB1 knockdown group in vivo.	Sorafenib	0-9	high mobility group box 1	Homo sapiens	55-60	
29246127-15	2017	The amount of mitochondrial HMGB1 decreased, while the amount of cytosolic HMGB1 increased following the exposure to sorafenib.	Sorafenib	117-126	high mobility group box 1	Homo sapiens	28-33	
29246127-15	2017	The amount of mitochondrial HMGB1 decreased, while the amount of cytosolic HMGB1 increased following the exposure to sorafenib.	Sorafenib	117-126	high mobility group box 1	Homo sapiens	75-80	
29246127-16	2017	Altogether, HMGB1 translocated from the mitochondria to the cytoplasm outside the mitochondria following the exposure of HepG2 cells to sorafenib.	Sorafenib	136-145	high mobility group box 1	Homo sapiens	12-17	
29246127-17	2017	CONCLUSIONS: A novel potential role of HMGB1 in the regulation of sorafenib therapy resistance in HCC was observed.	Sorafenib	66-75	high mobility group box 1	Homo sapiens	39-44	
29246127-18	2017	The knockdown of HMGB1 restores sensitivity to sorafenib and enhances HepG2 cell death, while HMGB1 overexpression blunts these effects.	Sorafenib	47-56	high mobility group box 1	Homo sapiens	17-22	
29246127-19	2017	The translocation of HMGB1 from the mitochondria to the cytosol following sorafenib treatment provides new insight into sorafenib resistance in HCC.	Sorafenib	74-83	high mobility group box 1	Homo sapiens	21-26	
29246127-19	2017	The translocation of HMGB1 from the mitochondria to the cytosol following sorafenib treatment provides new insight into sorafenib resistance in HCC.	Sorafenib	120-129	high mobility group box 1	Homo sapiens	21-26